Top Markets
Coin of the day
Crossject Société Anonyme Crossject Société Anonyme

Crossject Société Anonyme

ALCJ
Classifica tra le azioni #12721
Crossject Société Anonyme develops needle-free injection systems. The company... Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Prezzo delle azioni
$2.03
Capitalizzazione di mercato
$121.44M
Variazione (1 giorno)
-0.93%
Variazione (1 anno)
-1.97%
Paese
FR
Scambia Crossject Société Anonyme (ALCJ)

Categoria

Rapporto P/B per Crossject Société Anonyme (ALCJ)
Rapporto P/B al July 2026 TTM: -19.13
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Crossject Société Anonyme, il rapporto P/B attuale (TTM) è -19.13. Alla fine del 2023, era pari a -34.70.
Storico del rapporto P/B per Crossject Société Anonyme da 2010 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) -19.13 -49.09%
2024 -37.58 8.29%
2023 -34.70 -158.98%
2022 58.83 -594.78%
2021 -11.89 -81.50%
2020 -64.28 -524.02%
2019 15.16 54.90%
2018 9.79 46.48%
2017 6.68 29.69%
2016 5.15 -33.97%
2015 7.80 105.46%
2014 3.80 -92.39%
2013 49.91 -339.62%
2012 -20.83 12.72%
2011 -18.48 290.65%
2010 -4.73 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
8.0767 -142.21%
US
1.954 -110.21%
FR
5.8147 -130.39%
DE
8.564 -144.76%
JP
1.7598 -109.20%
US